天大药业中期报告2024

CONTENTS目錄 2Corporate Information3Management Discussion and Analysis6Disclosure of Interests and Other Information 10公司資料11管理層討論與分析14權益披露及其它資料 18Condensed Consolidated Statement of Profit or Lossand Other Comprehensive Income簡明綜合損益及其它全面收益表20Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表22Condensed Consolidated Statement of Changes in Equity簡明綜合權益變動表23Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表24Notes to the Condensed Consolidated Financial Information簡明綜合財務資料附註 CORPORATE INFORMATION NOMINATION COMMITTEE BOARD OF DIRECTORS Mr. Fang Wen Quan(Chairman)Mr. Lam Yat FaiMr. Chiu Sung Hong Mr. Fang Wen Quan(Chairman and Managing Director)Mr. Lui Man Sang RISK MANAGEMENT COMMITTEE Non-Executive Directors Mr. Chiu Sung Hong(Chairman)Mr. Fang Wen QuanMr. Lam Yat Fai Mr. Feng QuanmingMr. Zhong Tao PRINCIPAL BANKERS Independent Non-Executive Directors Agricultural Bank of ChinaBank of ChinaBank of CommunicationsChina Citic BankChina Merchants BankIndustrial and Commercial Bank of China Mr. Lam Yat FaiMr. Chiu Sung HongDr. Xian Yanfang AUDITOR Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong REGISTERED OFFICE Cricket SquareHutchins DriveP.O. Box 2681Grand CaymanKY1-1111Cayman Islands HONG KONG LEGAL ADVISER Woo, Kwan, Lee & Lo25th Floor, Jardine House1 Connaught Place, CentralHong Kong HEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS Suites 2405-2410, 24th FloorCITIC TowerNo. 1 Tim Mei AvenueCentralHong Kong COMPANY SECRETARYMr. Lo Tai On AUDIT COMMITTEE HONG KONG SHARE REGISTRAR ANDTRANSFER OFFICE Mr. Lam Yat Fai(Chairman)Mr. Chiu Sung HongDr. Xian YanfangMr. Zhong Tao Tricor Secretaries Limited17th Floor, Far East Finance Centre16 Harcourt RoadHong Kong REMUNERATION COMMITTEE PLACE OF LISTING Mr. Chiu Sung Hong(Chairman)Mr. Fang Wen QuanMr. Lam Yat FaiDr. Xian Yanfang The Stock Exchange of Hong Kong Limited STOCK CODE00455 CORPORATE WEBSITE www.tiandapharma.com MANAGEMENTDISCUSSIONANDANALYSIS BUSINESS REVIEW The Group’s business engages in three major segments, namely the Pharmaceuticals and medical technologiesbusiness, the Chinese medicine business, and the Medical and healthcare services. Seizing this opportunity, the Grouphas consolidated its core products, expanded sales channels, advanced the development of the traditional Chinesemedicine (“TCM”) businesses, and enriched product pipelines, continuously improving the operation of its three businesssegments. For the Pharmaceuticals and medical technologies business, after the aftershocks of the pandemic subsided andthe demand for medicines returned to normal, the demand for the “Four Types of Medicines” (antipyretic, coughsuppressant, antibiotic and antiviral) dropped sharply, and there was a significant drop in the demand for the Group’spediatric drugs, Tuoen®Ibuprofen. Nonetheless, the Tuoen still ranked among the top three in Mainland China in terms ofmarket share. During the renewal of the bidding of the centralized procurement of the Group’s cardio-cerebrovasculardrug, Tuoping®Valsartan capsules, in Jiangsu Province of the PRC, due to the adoption of the strategy of lower pricing bycompeting bidders, the sales volume of Tuoping for the Current Interim Period was affected. However, Tuoping was ableto maintain its position as the best-selling product of similar products in the hospital market in the PRC during the CurrentInterim Period. Meanwhile, the Group’s Tuoping was selected in the renewal of the bidding of the centralized procurementof the 13-province alliance led by Henan Province in the Current Interim Period, which opened up new provincial marketsand is expected to see a certain recovery in sales volume in 2025. For the Chinese medicine business, relying on its whole industrial chain build-up of traditional Chinese medicine, theGroup has focused on the trading of Chinese medicinal materials, Chinese medicinal decoction pieces and innovativeChinese medicines R&D, continuing to integrate high-quality resources in the industry chain’s upstream and downstreamsegments with a focus on variety management. In July last year, we signed a strategic cooperation framework agreementwith the Qiaocheng District Government of Bozhou city, Anhui Province, known as the “City of Chinese Medicine” andestablished a joint venture company, namely Tianda Chinese Medicine (Bozhou) Ltd.. During the Current Interim Period,we used the joint venture company as a platform to actively examine and explore the business of Chinese herbalmedicines varieties, and continued to pay attention to the construction of a strategic reserve of Chinese herbal medicinesin Bozhou and other development opportunities. For the medical and healthcare services, the Group has set up a new type of Chinese medicine clinic “TDMall”, withthe core positioning of “specialist treatments and specialized services, effectiveness and efficacy, combination of reco